Group 1 - The core project "Rapid Confirmation and Precise Prevention and Control of Emerging Viral Infectious Diseases" won the second prize of Jiangsu Province Science and Technology Progress Award, highlighting the company's achievements in technological innovation [1] - The project was led by Jiangsu Provincial Center for Disease Control and Prevention, with the company contributing core technological innovations in the field of inactivated enterovirus vaccines [1] - The project addresses key challenges in the prevention and control of emerging viral infectious diseases, establishing an efficient response system [1] Group 2 - The company has developed bivalent and quadrivalent inactivated enterovirus vaccines (Vero cells), which received clinical trial approval from the National Medical Products Administration in February 2025 [2] - Currently, there are no approved bivalent or quadrivalent enterovirus vaccines available globally, indicating a significant market opportunity for the company [2] - Successful development of these vaccines will enhance the company's multi-valent vaccine portfolio, strengthening its core competitiveness and market position [2]

Core Viewpoint - Shenzhen Kangtai Biological Products Co., Ltd. has achieved significant recognition in the field of vaccine research and development, particularly through its subsidiary Beijing Minhui Biological Technology Co., Ltd., which recently won the second prize of the Jiangsu Provincial Science and Technology Progress Award for its project on rapid confirmation and precise prevention of emerging viral infectious diseases [1][2]. Group 1: Project Recognition - The project "Key Technology Innovation and Application for Rapid Confirmation and Precise Prevention of Emerging Viral Infectious Diseases" addresses critical challenges in the prevention and control of new viral infectious diseases [1]. - The project was led by the Jiangsu Provincial Center for Disease Control and Prevention and nominated by the Provincial Health Commission, highlighting the importance of collaboration in public health initiatives [1]. Group 2: Vaccine Development - Minhui Biological's independently developed inactivated virus vaccine platform is a core component of the project, receiving high recognition for its innovation, practicality, and scientific value [2]. - The company has successfully obtained clinical trial approval from the National Medical Products Administration for its bivalent and quadrivalent inactivated enterovirus vaccines, with the quadrivalent vaccine currently in Phase I clinical trials [2]. - There are currently no approved bivalent or quadrivalent enterovirus vaccines available globally, indicating a significant market opportunity for the company [2]. Group 3: Strategic Implications - The recent award is seen as a validation of the company's commitment to independent innovation and its comprehensive strength in vaccine research and development, which is expected to enhance its core competitiveness and influence in the market [2]. - Successful development of these vaccines could further enrich the company's multi-valent vaccine portfolio, solidifying its market position and providing a strong foundation for sustainable growth [2].